Search

Sipuleucel-T Prolongs Survival in Metastatic Prostate Cancer - OncologySTAT

Sipuleucel-T Prolongs Survival in Metastatic Prostate Cancer - OncologySTAT


Elsevier Global Medical News. 2010 Jul 28, M Moon


The immunotherapy sipuleucel-T significantly prolonged survival in a study of 512 men with metastatic castration-resistant prostate cancer, confirming the results of two smaller previous trials of this therapeutic "cancer vaccine," according to a report in the July 29 issue of the New England Journal of Medicine.
The experimental treatment increased median survival by 4.1 months and raised the estimated probability of 3-year survival from 23% to 32%, compared with placebo, significant improvements in this population of men with advanced disease, said Dr. Philip W. Kantoff of the Dana-Farber Cancer Institute and Harvard Medical School, Boston, and his coauthors.